Join
Live feed
·
PRReleasevia Quantisnow
Replimune Group Inc. logo

Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

ByQuantisnow·Wall Street's wire, on your screen.
REPL· Replimune Group Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track REPL (Replimune Group Inc.) and more on Quantisnow.